Our News
Glioblastoma (GBM)'s median overall survival is almost 21 months. Six phase 3 immunotherapy clinical trials have recently been published, yet 5/6 did not meet approval by regulatory bodies. For the sixth, approval is uncertain.
Glioblastoma (GBM) is a primary brain cancer with a devastating prognosis with limited treatment options. Stereotactic biopsies are performed routinely for histological and molecular diagnosis, but could they also be performed for detailed multi-omics investigation into the tumor microenvironment?
Enroll in the trial
Exvade is conducting a First-in-Human study of the Tumor Monorail Device at the Preston Robert Tisch Brain Tumor Center at Duke University, evaluating its safety and advancing a transformative shift in how cancer is treated.
Enroll in our clinical trial and contribute to the development of innovative solutions that prioritize patient care and outcomes.
“By allowing real-time monitoring of the tumor over time, while on therapy, we will hopefully be able to more swiftly identify the degree of efficacy or the limitations of our therapies, while preventing the trauma and costs of repeated brain surgery.”
- Dr. Annick Desjardins, MD, FRCPC, neuro-oncologist,
professor of neurosurgery and neurology at Duke University
